Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting

Lyell Immunopharma, Inc. has successfully transferred its LYL273 cancer treatment manufacturing process to its facility in Bothell, Washington, after receiving approval from the U.S. Food and Drug Administration. The improved manufacturing process and updated analytical methods aim to boost performance and capacity at the company's LyFE Manufacturing Center.

LYL273 is a CAR T-cell product candidate designed to treat patients with relapsed/refractory metastatic colorectal cancer. The ongoing Phase 1/2 clinical trial, known as CARABiNER, seeks to determine the recommended Phase 2 dose and optimize safety management. In June 2026, Lyell shared safety data indicating that a gastrointestinal prophylaxis reduced diarrhea/colitis from 55% to 10%.

The LyFE Manufacturing Center has the capability to manufacture over 1,200 CAR T-cell doses annually. Lynn Seely, Lyell's President and CEO, expressed focus on determining the recommended Phase 2 dose and optimizing safety management based on trial results.